Dr. Reddy's Laboratories Limited

BOVESPA:R1DY34 Stock Report

Market Cap: R$71.8b

Dr. Reddy's Laboratories Future Growth

Future criteria checks 0/6

Dr. Reddy's Laboratories's earnings are forecast to decline at 1.6% per annum while its annual revenue is expected to grow at 5.3% per year. EPS is expected to decline by 2.9% per annum. Return on equity is forecast to be 15.2% in 3 years.

Key information

-1.6%

Earnings growth rate

-2.9%

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth rate5.3%
Future return on equity15.2%
Analyst coverage

Good

Last updated03 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BOVESPA:R1DY34 - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027326,57348,48450,54365,81020
3/31/2026338,08259,33853,28268,27135
3/31/2025314,61556,97437,26462,90933
6/30/2024288,50755,57921,01242,679N/A
3/31/2024279,16455,68418,01945,433N/A
12/31/2023271,30252,20628,71353,592N/A
9/30/2023266,85450,88849,17972,115N/A
6/30/2023261,10947,21641,12363,470N/A
3/31/2023245,87945,06740,00958,875N/A
12/31/2022237,27936,35029,17048,315N/A
9/30/2022222,77630,94421,86642,386N/A
6/30/2022217,35129,73616,75538,211N/A
3/31/2022214,39123,56812,00528,108N/A
12/31/2021207,30726,31714,97630,255N/A
9/30/2021203,40619,4501,59717,194N/A
6/30/2021194,74117,1537,33521,342N/A
3/31/2021189,72217,23823,14235,703N/A
12/31/2020186,75621,25615,52826,983N/A
9/30/2020181,29815,36122,02630,069N/A
6/30/2020180,34018,66324,35430,921N/A
3/31/2020174,60019,49823,98529,841N/A
12/31/2019170,44816,20028,93034,006N/A
9/30/2019165,11026,74937,51142,937N/A
6/30/2019155,07920,86237,40043,559N/A
3/31/2019153,85118,79521,21328,704N/A
12/31/2018149,03417,47319,95327,774N/A
9/30/2018148,59415,9659,57619,007N/A
6/30/2018145,90313,7764,49014,986N/A
3/31/2018141,8559,806N/A18,029N/A
12/31/2017141,8279,909N/A20,765N/A
9/30/2017140,58811,266N/A18,478N/A
6/30/2017140,90711,367N/A14,480N/A
3/31/2017139,87012,039N/A21,513N/A
12/31/2016141,2699,660N/A22,252N/A
9/30/2016144,12710,751N/A29,018N/A
6/30/2016148,41015,019N/A37,693N/A
3/31/2016153,86620,013N/A41,247N/A
12/31/2015155,85024,456N/A42,252N/A
9/30/2015154,60224,409N/A36,012N/A
6/30/2015150,59222,932N/A29,083N/A
3/31/2015147,36022,179N/A25,033N/A
12/31/2014143,47421,806N/A22,860N/A
9/30/2014140,38022,247N/A23,151N/A
6/30/2014138,07623,409N/A19,532N/A
3/31/2014132,17021,515N/A19,463N/A
12/31/2013130,04322,409N/A13,951N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: R1DY34's earnings are forecast to decline over the next 3 years (-1.6% per year).

Earnings vs Market: R1DY34's earnings are forecast to decline over the next 3 years (-1.6% per year).

High Growth Earnings: R1DY34's earnings are forecast to decline over the next 3 years.

Revenue vs Market: R1DY34's revenue (5.3% per year) is forecast to grow slower than the BR market (7.7% per year).

High Growth Revenue: R1DY34's revenue (5.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: R1DY34's Return on Equity is forecast to be low in 3 years time (15.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y